Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

CVS Health Corp.
CVS - NYSE - $83.85 (as of ) ▲ +3.10%
-
Earnings Tue 9 Feb

CVS opens the
books on Tuesday evening.

The median of 10 price targets is $1121, stock is $84, +33.6% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
A-
Council 4/6 - Historical V1 score 39

A- — FMP rating1. Form 4: 6 transactions1.

Quick Answer

CVS Health Corporation (CVS) Q4 consensus: revenue $107.2B1, EPS $1.171. 8 consecutive quarters of beat1.

$1.17 EPS Estimate Last year $1.09 - +7% YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q3 FY26 EPS $2.09 vs $1.65 estimate: beat (+26.7%)1. Stock move on the next trading day: +1.7%1.

Next report

What to watch in Q4 FY26 (Feb 9, 2027)

  • EPS: consensus $1.17, against $1.09 in the same quarter a year ago (+7%).
  • Revenue: consensus $107.2B.

Watchlist

6 metrics stand out this quarter.

$900 million Risk Indicator

Healthcare Benefits Margin Recovery

Healthcare Benefits delivered $900 million of adjusted operating income in Q3 with a medical benefit ratio of 91.3%.

"In the quarter, we delivered adjusted operating income of $900 million an increase of nearly $600 million from the prior year quarter. Our medical benefit ratio was 91.3%."

- Brian O. Newman, CFO - Q3 FY26 Earnings Call - November 4, 2026
$8.20 Expectation / Guide

Fy26 Eps Guidance Raise

CVS raised its full-year 2026 adjusted EPS guidance to at least $8.20 from a prior range of $7.90 to $8.10.

David Joyner, Chairman and CEO - Q3 FY26 Earnings Call - November 4, 2026
$8.65 Expectation / Guide

Fy27 Eps Outlook

Management expects at least $8.65 of adjusted EPS in 2027, about 13% growth off an adjusted 2026 baseline.

Brian O. Newman, CFO - Q3 FY26 Earnings Call - November 4, 2026
$7 billion Investor Focus

Health Services 2027 Floor

Health Services is expected to deliver at least $7 billion of adjusted operating income in 2027, which management frames as trough earnings for the segment.

Brian O. Newman, CFO - Q3 FY26 Earnings Call - November 4, 2026
$2.09 Investor Focus

Q3 Adjusted Eps

Q3 adjusted EPS of $2.09 rose more than 30% from the prior-year quarter.

Brian O. Newman, CFO - Q3 FY26 Earnings Call - November 4, 2026
2 Investor Focus

Separation Announcement

CVS Health announced its intention to separate into two independent publicly traded companies: a healthcare solutions company and CVS Pharmacy.

"Today, announced our intention to separate into 2 independent publicly traded companies."

- David Joyner, Chairman and CEO - Q3 FY26 Earnings Call - November 4, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 4 / 6 Bullish

6 investor frameworks. 4 bullish (Ray Dalio, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +33.6%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 40
Klarman value - target upside +33.6%
Buffett quality - ROE score 4/5
Munger valuation - target upside +33.6%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
39.9 RSI 39.9 weak momentum, 50d below
MACD
-7.20 price below 50d - resistance dominant
50d MA
$90 stock 7.2% below - short-term resistance
200d MA
$89 stock 5.7% below - long-term pressure
Volume (10d)
+21% increase - pre-earnings positioning
Resistance
$112
Analyst median target - upgrade trigger if broken
Current
$84
Pre-earnings position
Support
$76
Invalidation - close below this is a technical breakdown
Pattern
Range
$76-$112 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q4 FY25
$1.09 vs $1.00 est · Next-day price move: +1.9%
BEAT
Q1 FY26
$2.57 vs $2.18 est · Next-day price move: +0.6%
BEAT
Q2 FY26
$2.58 vs $1.85 est · Next-day price move: -2.9%
BEAT
Q3 FY26
$2.09 vs $1.65 est · Next-day price move: +1.7%

Three scenarios: what could happen?

EPS < $1.13 (no guidance)

Brian O. Newman].

Backlog concentration

No RPO/backlog concentration disclosed in Q3 earnings call.

Insider trading signal

Form 4 Q3 FY26: 6 transactions, net -$280.77M1.

Executive Action Amount Date
Shah Prem S EVP and Group President Purchase +$2.00M 2026-11-06
ROBBINS LARRY director Sale -$187.33M 2026-05-21
ROBBINS LARRY director Sale -$14.4K 2026-05-21
ROBBINS LARRY director Sale -$74.56M 2026-05-21
ROBBINS LARRY director Sale -$14.48M 2026-05-21
ROBBINS LARRY director Sale -$6.40M 2026-05-21

6 transactions · 5 sales / 1 purchases = net negative flow. Not large in absolute terms against a $107.2B market cap.

CapEx shock

Q3 CapEx $817.0M1. Q3 op margin 3.3%1 - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $1.17 + CapEx discipline
Threshold: EPS > $1.171.
Target: Break above median target $1121; high target $1231 upper bound.
Scenario B - In-Line
EPS approx $1.17 + CapEx < $817.0M
Threshold: EPS approx $1.171, Q4 CapEx < $817.0M1.
Target: Consolidation in the band between current $841 and median $1121.
Scenario C - Miss
EPS < $1.13 or CapEx >= $817.0M
Threshold: EPS < $1.131.
Current price $84 — below SMA200 $891.

Market Outlook

What do analysts say? 10 price targets · 27 ratings

Wall Street Consensus
$112
12-month median target price (+33.6% gap to the analyst consensus median)
25
BUY
2
HOLD
0
SELL
Risk Management
$76
Invalidation level - critical support threshold
$90 - 50-day MA (below, -7.2%)
$89 - 200-day MA (below, -5.7%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - CVS Q4 FY26
A-

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $1.171, CapEx threshold "below $817.0M". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Feb 9, 2027EARNINGSQ4 FY26 results (after market close) + earnings call
Feb 10, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Mar 1, 2027 – Mar 31, 2027FILING10-K due within 60–90 days of fiscal year end (by Mar 1, 2027 – Mar 31, 2027); the exact deadline depends on filer status
~May 12, 2027EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the CVS Q4 FY26 earnings preview cover?

This CVS Health Corporation (CVS) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in CVS Q4 FY26 earnings?

CVS Health Corporation (CVS): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

CVS Health Corporation (CVS): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

CVS Health Corporation (CVS): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded